Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Cerenome rebrand to CNSY with CNSide and REYOBIQ milestones

Aug 14, 2026, 4:23 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Multiple near-term catalysts: rebrand to CNSY, REYOBIQ trial progress (LM/GBM/PBC), CNSide payer coverage expansion, and a potential FDA End-of-Phase 2 meeting in 2027. However, near-term cash burn and need for additional financing create financing risk that could cap upside.

AI summary

What happened, with direct paths to the underlying reporting

Cerenome, formerly Plus Therapeutics, announced Q2 2026 results alongside a corporate rebrand to CNSY. The company highlighted progress on REYOBIQ trials (LM, GBM, PBC) and CNSide payer coverage reaching 150 million lives, with CAP accreditation and AI/data initiatives. Near-term catalysts include GBM data in 2027 and expanded payer coverage, potentially lifting valuation if funding remains available.

Rebranded to Cerenome; CNSY began trading on Nasdaq Capital Market. Effective Aug 3, 2026.
REYOBIQ enrollment advancing; LM trial ~1/3 enrolled with no dose-limiting toxicities.
GBM Phase 2 enrollment to finish in 2026; data readout and FDA meeting.
CNSide tests: 232 in H1 2026; 150M covered lives by mid-year.
Q2 2026 cash $8.6M; net loss $9.0M; CPRIT grant revenue $0.4M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.